focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

Diurnal treatment gets approval from Welsh regulatory body

Fri, 07th Oct 2022 13:01

(Alliance News) - Diurnal Group PLC on Friday said its Efmody treatment has been recommended as an option to treat patients with congenital adrenal hyperplasia.

Diurnal is a Cardiff-based pharmaceutical company focused on hormonal diseases. Its treatment was recommended by the All Wales Medicines Strategy Group as an option for restricted use in NHS Wales.

The recommendation means Efmody is available as a second-line treatment option in adolescents with congenital adrenal hyperplasia and as third-line treatment in adults with the disease.

In both cases, the treatment is restricted to patients who are not adequately controlled on maximum guideline doses of immediate-release hydrocortisone.

Efmody is a preparation of hydrocortisone that has been specifically designed to mimic the circadian rhythm of cortisol. It is designed to control androgen excess and chronic fatigue in patients with diseases of cortisol deficiency.

Congenital adrenal hyperplasia refers to a group of genetic disorders that affect the adrenal glands, a pair of small organs above the kidneys. The adrenal glands produce important hormones, including Cortisol, which regulates the body's response to illness or stress.

Diurnal will commercially roll-out Efmody in Wales using its existing sales and marketing infrastructure and supply chain.

Interim Chief Executive Officer Richard Bungay commented: "We are delighted that, after a rigorous review, the All Wales Medical Strategy Group has recognised the potential for Efmody to address important unmet needs in patients suffering with congenital adrenal hyperplasia. Diurnal believes the use of this medicine will improve the lives of adults and adolescents in Wales living with this rare disease."

Shares in Diurnal were trading 0.9% lower at 26.90 pence each in London on Friday afternoon.

By Chris Dorrell; chrisdorrell@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

Related Shares

More News
28 Oct 2022 21:18

TRADING UPDATES: SulNOx, Marwyn loss widens; Kropz gets new facility

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

21 Oct 2022 21:29

TRADING UPDATES: Trackwise Designs wins deal; Cake Box names CFO

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News:

14 Oct 2022 15:48

UK shareholder meetings calendar - next 7 days

7 Oct 2022 11:31

Diurnal's 'Efmody' treatment gets thumbs-up for NHS Wales

(Sharecast News) - Specialty pharmaceutical company Diurnal Group announced on Friday that the All-Wales Medicines Strategy Group (AWMSG) has recommen...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.